Premium
Repeated administration of high‐dose depot medroxyprogesterone acetate does not alter SHIV SF 162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings
Author(s) -
Srinivasan Priya,
Zhang Jining,
Dinh Chuong T.,
Teller Ryan S.,
McNicholl Janet M.,
Kiser Patrick F.,
Herold Betsy C.,
Smith James M.
Publication year - 2017
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/jmp.12299
Subject(s) - medroxyprogesterone acetate , pharmacokinetics , viremia , medicine , medroxyprogesterone , viral shedding , viral load , andrology , gynecology , pharmacology , hormone , physiology , human immunodeficiency virus (hiv) , virology , virus
Background Intravaginal rings ( IVR ) for HIV prevention will likely be used by women on depot medroxyprogesterone acetate ( DMPA ) hormonal contraception. We used pigtailed macaques to evaluate the effects of DMPA on tenofovir disoproxil fumarate ( TDF ) IVR pharmacokinetics and viral shedding. Methods Mucosal tenofovir ( TFV ) levels were compared in SHIV SF 162p3 ‐negative DMPA ‐treated (n=4) and normally cycling (n=6) macaques receiving TDF IVR s. Plasma viremia and vaginal shedding were determined in groups of SHIV SF 162p3 ‐positive DMPA ‐treated (n=6) and normally cycling (n=5) macaques. Results Similar median vaginal fluid TFV concentrations were observed in the DMPA ‐treated and cycling macaques over 4 weeks (1.2×10 5 and 1.1.×10 5 ng/ mL , respectively). Median plasma viremia and vaginal shedding AUC of the DMPA ‐treated (2.73×10 7 and 8.15×10 4 copies/ mL , respectively) and cycling macaques (3.98×10 7 and 1.47×10 3 copies/ mL , respectively) were statistically similar. Conclusions DMPA does not affect TDF IVR pharmacokinetics or SHIV shedding.